The Food and Drug Administration on April 24 said it will seek fast trials for three psychedelic drugs, including psilocybin, one week after President Donald Trump’s directive to accelerate access to psychedelic treatments for mental health conditions.
Three national priority vouchers are being issued, including two for psilocybin, the FDA said in a statement.
One of the companies receiving a voucher is developing psilocybin for depression that resists other treatments. Another has been developing psilocybin for major depressive disorder.
The third voucher is going to a company that has been testing methylone in post-traumatic stress disorder patients.
Trump on April 18 issued an order that directed health officials to establish a pathway to authorizing psychedelic drugs, saying they have shown potential in clinical trials against mental illness. Psychedelics can cause hallucinations and are currently banned in the United States….